DOCSLIB.ORG

Paris NASH Meeting 2019 Poster – Selective ROCK2 Inhibitors for The

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Paris NASH Meeting 2019 Poster – Selective ROCK2 Inhibitors for The Selective ROCK2 inhibitors for the treatment of fibrosis Emily P. Offer; Stuart A. Best; Nicolas E.S. Guisot; Phillip MacFaul; Sara Ceccarelli; Matthew R. Box; Neil Hawkins; Rosie Knowles; Amy Cooke; Alison Hunter; Charles Crossland; Sam Smith; Rebecca Holland; Peter Bunyard; Clifford D. Jones; Richard Armer. Redx Pharma Plc, Alderley Park, Macclesfield, United Kingdom. INTRODUCTION RESULTS ROCK2 is central to disease processes driving fibrosis pathology Redx’s ROCK2 inhibitors are potent and highly selective • The Rho Associated Coiled-Coil Containing Protein Kinase (ROCK) serine/threonine kinases, ROCK1 and • Redx’s ROCK2 series of compounds are potent and highly selective against ROCK1 and a panel of kinases, ROCK2, are central signalling proteins that regulate a range of cellular responses. tested in biochemical and cellular mechanistic assays. • These processes are central to • Cellular potency of ROCK2 selective inhibitors determined by inhibition of pMYPT1, a substrate the aberrant wound healing downstream of ROCK; ROCK1 or ROCK2 selective cell lines were generated with shRNA. response that can progress to KD025 REDX10178 REDX10616 REDX10843 Assay ROCK cellular signalling chronic injury and organ IC50 (µM) IC50 (µM) IC50 (µM) IC50 (µM) fibrosis. ROCK2 activity 0.16 0.002 0.004 0.017 • ROCK pathway inhibition ROCK1 activity 9.8 0.2 3.0 2.5 decreases fibrosis in vivo and Cellular ROCK2 selective pMYPT1 1.0 0.9 1.0 2.4 fibrotic markers in vitro. Cellular parental MCF7 pMYPT1* 0.9 4.1 22 24 • ROCK2 is upregulated in Cellular ROCK1 selective pMYPT1* > 30 20 > 30 26 diseases associated with acute Table 1. Selective ROCK2 compounds activity in biochemical and cellular assays. Comparison with KD02522. *Selective ROCK2 compounds expected to be less active in parental & ROCK1 selective MCF7 assays. and chronic inflammation, for A: ROCK expression in MCF7 cell lines B: pMYPT1 mechanistic assay example where damage is ) 120 Parental MCF7 % ( 100 ROCK1 KD caused by high glucose and n o ROCK2 KD i t i 80 b parental parental i ROCK1 KD ROCK1 ROCK2 KD ROCK2 high fat diets. h n 60 i ROCK1 e g 40 a • ROCK2 increased in liver t n 20 GAPDH e c r fibrosis models and the e 0 ROCK2 P increased ROCK2 signalling 10-9 10-8 10-7 10-6 10-5 10-4 GAPDH [REDX10843] (M) drives HSC activation. Figure 1. ROCK2 is downstream of fibrosis mediators and drives pathways associated with fibrosis pathology. Figure 2. MCF7 KD lines generated with shRNA express only one isoform (A). Representative inhibition of pMYPT1 in parental and ROCK1 or ROCK2 knockdown cell lines. RESULTS Assay REDX10843 REDX10843 has suitable in vitro ADME properties and is orally bioavailable 9 targets >90% inhibition; Kinase panel (468 kinases) at 10 µM 32 targets >50% inhibition A: Mouse PK of REDX10843 B: Rat PK of REDX10843 Selectivity • REDX10843 is highly selective across a panel of No target > 50% inhibition; 100 10 CEREP SafetyScreen44 at 10 µM 468 kinases, and in the CEREP safety panel 8 targets > 25% inhibition ) 50 mg/kg REDX10843 ) 100 mg/kg REDX10843 M M 10 mg/kg REDX10843 30 mg/kg REDX10843 hERG IC > 33 µM ( ( 50 with no significant off target activities 10 n n 1 o o Cardiotoxicity hNav1.5 IC > 100 µM i i 50 t t a observed. a r r t 1 t hCav1.2 IC50 > 100 µM n n e e c • No activity in cardiotoxicity assays. c 0.1 Mini-Ames 5 strains No significant increase in n n o o Genotoxicity C 0.1 C numbers of revertant colonies ( S9 plate based) d • No genotoxicity or mutagenicity observed in in d n n u u 0.01 Micronucleus test using TK6 cells No statistically significant o o Mutagenicity b vitro tests. 0.01 b n n ( S9 metabolic activation) increase in micronuclei U U Mouse Rat Dog Human • Low to medium in vitro clearance, conserved 0.001 0.001 0 4 8 12 16 20 24 0 4 8 12 16 20 24 Microsome stability CLint (µL/min/mg) 35 39 15 4.9 across species (mouse, rat, dog and human) Time (h) Time (h) Hepatocyte stability CLint (µL/min/106 cells) 18 15 19 2.3 and good oral exposure in mouse, rat and dog. Plasma protein binding Percentage free (Fu %) 13 14 23 13 Figure 3. Oral pharmacokinetic profiles of REDX10843 dosed in C57Bl/6 mice (A) and Han Wistar rats (B). Formulation: HPMC (0.5% w/v in water) / DMSO [90:10]. Table 2. In vitro properties for REDX10843. ROCK2 inhibitors reduce fibrosis markers in kidney models in vitro and in vivo ROCK2 inhibitors reduce fibrosis markers in liver models in vitro and in vivo A: ROCK2 selective compounds inhibit in vitro expression of fibrosis markers in kidney mesangial cells A: ROCK2 selective compounds reverse myofibroblast phenotype in HSC derived myofibroblasts in vitro • Mesangial cells cultured in high glucose for 9 days; model diabetic environment (compounds day 4-9). • Hepatic stellate cell line differentiated on stiff plastic for 2 weeks demonstrate myofibroblast • Protein expression of CTGF, fibronectin, PDGF-BB, TIMP-1 and MCP-1 detected in the culture media. morphology and phenotype by induction of αSMA protein expression. CTGF expression in culture supernatant • Reduction of αSMA with ROCK2 inhibitors indicates suppression of the myofibroblast phenotype. KD025 REDX10178 REDX10616 REDX10843 n 120 o ASSAY i IC (µM) IC (µM) IC (µM) IC (µM) s A: Expression of αSMA in LX2 myofibroblasts B: QuantificationRED ofX1 0α6SMA16 in LX2 myofibrolastsREDX10843 50 50 50 50 s 100 e ) l r 120 100 o p r 80 DMSO REDX10843: 1 µM x CTGF assay (WB) Inactive 0.4 1.5 t 0.4 ) e l n n 100 n o 80 o ) o F o r i l i t c 60 s s o n G r s f s 80 o T t Secreted TIMP-1 e e 0.9 0.2 0.9 2.8 c o r n r 60 C p o O 40 p e x c x % 60 S ( e e v f M i o t 40 D A A Secreted PDGF-BB 2.9 0.2 0.4 1.4 20 a 40 f l M M % o ( e S S % R 20 Secreted MCP-1 10 0.3 0.3 2.2 0 20 ( O M M M M M M M S µ µ µ µ µ µ µ 0 0 M 0 5 5 .3 8 2 5 D 2 .2 0 .0 .0 0 10 3 1 0.4 0.1 0.04 0.01 10 3 1 0.4 0.1 0.04 0.01 Secreted MMP2 ND 1.2 2.2 1.1 1 0 0 .0 0 REDX10616 concentration (µM) REDX10843 concentration (µM) [REDX10616] C: Mean IC50 of percentage inhibition of αSMA Table 3. Summary of analysis of culture supernatant from cells cultured with Redx’s ROCK2 inhibitors and Figure 4. Representative data for REDX10616 inhibition of Assay KD025 (IC50) REDX10178 (IC50) REDX10616 (IC50) REDX10843 (IC50) KD025 as a comparison. Supernatant analysed by western blot (CTGF) or ELISA. Data are from n≥3. CTGF. αSMA expression 0.3Fib rµMosis area (Siriu0.7s R eµMd) 0.3 µM 0.5 µM Figure 6. Redx ROCK2 inhibitors reduces αSMA expression in LX-2 differentiated myofibroblasts. Myofibroblasts expressing αSMA are dosed with compound for 48 h and ) B: ROCK2 inhibition of inflammatory response in vivo, in a model of acute kidney injury ) *** Fibros2i.s0 area (Sirius Red) % % ( αSMA expression detected( by IHC. Representative images shown where green indicates αSMA and purple nuclei stain (DRAQ5) (A). Representative data of cells dosed ** a a ** ) ) e • Cisplatin induces an acute inflammatory infiltrate and with REDX10616 or REDX10843e (n=4*** ) (B). Table of mean quantification of αSMA expression IC50 of inhibition response (C). r 2.0 r % % a a 1.5 ( ( ** e Fibroe sis area (Sirius Red) C: Gene expression in the kidney * a a ** v response in the kidney. v e e i i t t r Nephrin r i i * a a ) ) 1.5 *** s s B: REDX10843 1 .significantly0 reduces fibrosis parameters in the STAM NASH model Nephrin * e e o 2.0 o % % * * ( ( v v p p ** i • This inflammatory response induces injury in the kidney Bcl2 i * t t a a i Nephrin i * d d ** * e e s s e Bcl2 • Selective e ROCK2 inhibitor REDX10843 dosed therapeutically in the murine STAM NASH model r r * 1.0 o o * * R R 0.5 a a * and leads to an increase in the expression of ROCK2. 1.5 * p Fibronectin p * s Bcl2 s e e * d d u u v v significantly reduces fibrosis in the liver when dosed BID or QD at 50 mg/kg. Fibronectin * i i i i e e * t t * r † ‡ r * i i i i R Collagen 1 R 0.5 * * s • ROCK2 selective inhibitors REDX10178 and REDX10616 , s 0.0 S Fibronectin 1.0 S * s s o o Collagen 1 * u u p p i i * * r r * Reticular Fibroblasts (ER-TR7) i A: Siriusi Red expression in the liver B: Reticular fibroblasts (ER-TR7) d MMP-3 d reduce the expression of genes associated with Collag* en 1 Fibrosis area (Sirius Red) e e 0.0 * S S MMP-3 * R R 0.5 ** * * * ) s inflammation and fibrosis in a dose dependent manner. MMP-2 s *** 6 MMP* -3 *** u 2u .0 ** % * i i Control Telmisartan 10 mg/kg QD ( r r ** MMP-2 * i i * a ) * ** * 0.0 e S S Vehicle QD REDX10843 50 mg/kg QD TIMP-1 e * r % MMP* -2 n ( a * 1.5 e Vehicle BID REDX10843 50 mg/kg BID e Control Telmisartan 10 mg/kg QD TIMP-1 a * e 4 A: Schematic of dosing regime * n e v * G i r e CTGF e Vehicle QD REDX10843 50 mg/kg QD TIMP-1 t * i a n s G e CTGF * 1.0 Cisplatin 25 mg/kg IP e Vehicle BID REDX10843 50 mg/kg BID o * v p i G TGFß t CTGF * Control Telmisartan 10 mg/kg QD i d 2 * s e Day TGFß * 0 1 2 3 4 o * Vehicle QD REDX10843 50 mg/kg QD R 0.5 * * IL-6 P TGFß s * Vehicle BID REDX10843 50 mg/kg BID u * i r IL-6 * * i * * 0.0 0 IL-6 ICAM-1 S * * ICAM-1 * Compound treatment QD * * ICAM-1 * IL-1ß * * * IL-1ß * * IL-1ß TNFa * Control Telmisartan 10 mg/kg QD * B: Kidney protein expression of ROCK2 * Vehicle QD REDX10843 50 mg/kg QD * TNFa * * TNFa MCP-1 * Vehicle BID REDX10843 50 mg/kg BID * 0 .0 1 0 * * MCP-1 * MCP-1 * 0 .0 0 8 -100 -80 -60 -40 -20 0 20 H D P -100 -80 -60 -40 -20 0 20 A 0 .0 0 6 -100 -80 -60 -40 Cha-2n0ge from0 vehic2le0 (%) G / 2 Change from vehicle (%) K 0 .0 0 4 C Change from vehicle (%) O R 0 .0 0 2 REDX10616 50 mg/kg QD REDX10616 50 mg/kg QD REDX10616 10 mg/kg QD REDX10616 50 mg/kg QD 0 .0 0 0 REDX10616 10 mg/kg QD n a iv e c is p la tin REDX10616 10 mg/kg QD Figure 5.
Load more

Recommended publications
  • Masre, Siti Fathiah (2015) Analysis of ROCK2 Activation in Transgenic Mouse Skin Carcinogenesis. Phd Thesis
    Masre, Siti Fathiah (2015) Analysis of ROCK2 activation in transgenic mouse skin carcinogenesis. PhD thesis. http://theses.gla.ac.uk/6628/ Copyright and moral rights for this thesis are retained by the author A copy can be downloaded for personal non-commercial research or study This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the Author The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the Author When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given Glasgow Theses Service http://theses.gla.ac.uk/ [email protected] Analysis of ROCK2 Activation in Transgenic Mouse Skin Carcinogenesis Siti Fathiah Masre A Thesis submitted to the University of Glasgow In fulfilment of the requirements for the Degree of Doctor of Philosophy School of Medicine College of Medical, Veterinary and Life Sciences University of Glasgow August 2015 2 Summary The purpose of this study was to investigate ROCK2 activation in squamous cell carcinogenesis and assess its co-operation with rasHa and fos oncogene activation together with loss of PTEN mediated AKT regulation. The analysis of ROCK deregulation with these genes in the MAP Kinase and PI3K pathways, two of the most commonly deregulated signalling systems, employed a well-characterised, transgenic mouse skin model of multi-stage carcinogenesis. A major goal was to study co-operation between these genes in the conversion of benign tumours to malignancy and investigate subsequent progression to aggressive carcinomas, given these are the most significant clinical stages of carcinogenesis from a patient’s viewpoint; and also investigated effects of ROCK2 deregulation on the processes of normal epidermal differentiation.
    [Show full text]
  • Identification and Characterization of RHOA-Interacting Proteins in Bovine Spermatozoa1
    BIOLOGY OF REPRODUCTION 78, 184–192 (2008) Published online before print 10 October 2007. DOI 10.1095/biolreprod.107.062943 Identification and Characterization of RHOA-Interacting Proteins in Bovine Spermatozoa1 Sarah E. Fiedler, Malini Bajpai, and Daniel W. Carr2 Department of Medicine, Oregon Health & Sciences University and Veterans Affairs Medical Center, Portland, Oregon 97239 ABSTRACT Guanine nucleotide exchange factors (GEFs) catalyze the GDP for GTP exchange [2]. Activation is negatively regulated by In somatic cells, RHOA mediates actin dynamics through a both guanine nucleotide dissociation inhibitors (RHO GDIs) GNA13-mediated signaling cascade involving RHO kinase and GTPase-activating proteins (GAPs) [1, 2]. Endogenous (ROCK), LIM kinase (LIMK), and cofilin. RHOA can be RHO can be inactivated via C3 exoenzyme ADP-ribosylation, negatively regulated by protein kinase A (PRKA), and it and studies have demonstrated RHO involvement in actin-based interacts with members of the A-kinase anchoring (AKAP) cytoskeletal response to extracellular signals, including lyso- family via intermediary proteins. In spermatozoa, actin poly- merization precedes the acrosome reaction, which is necessary phosphatidic acid (LPA) [2–4]. LPA is known to signal through for normal fertility. The present study was undertaken to G-protein-coupled receptors (GPCRs) [4, 5]; specifically, LPA- determine whether the GNA13-mediated RHOA signaling activated GNA13 (formerly Ga13) promotes RHO activation pathway may be involved in acrosome reaction in bovine through GEFs [4, 6]. Activated RHO-GTP then signals RHO caudal sperm, and whether AKAPs may be involved in its kinase (ROCK), resulting in the phosphorylation and activation targeting and regulation. GNA13, RHOA, ROCK2, LIMK2, and of LIM-kinase (LIMK), which in turn phosphorylates and cofilin were all detected by Western blot in bovine caudal inactivates cofilin, an actin depolymerizer, the end result being sperm.
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • Genomic Characterization of Additional Cancer-Driver Genes Using a Weighted Iterative Regression Accurately Modelling Background Mutation Rate
    bioRxiv preprint doi: https://doi.org/10.1101/437061; this version posted October 8, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Genomic characterization of additional cancer-driver genes using a weighted iterative regression accurately modelling background mutation rate Lin Jiang1,2,#, Jingjing Zheng1, #, Johnny Sheung Him Kwan9,10,11,#, Sheng Dai1, Cong Li1, Ka Fai TO9,10,11, Pak Chung Sham5,6,7,8,*, Yonghong Zhu1,2,* and Miaoxin Li1,2,3,4,5,6,7* 1Zhongshan School of Medicine,2First Affiliated Hospital, 3Center for Genome Research, 4Center for Precision Medicine, Sun Yat-sen University, Guangzhou 510080, China; 5Key Laboratory of Tropical Disease Control (SYSU), Ministry of Education, Guangzhou 510080, China; 6The Centre for Genomic Sciences, 7Department of Psychiatry, 8State Key Laboratory for Cognitive and Brain Sciences, the University of Hong Kong, Pokfulam, Hong Kong; 9Department of Anatomical and Cellular Pathology, 10State Key Laboratory in Oncology in South China, 11Li Ka-Shing Institute of Health Sciences, The Chinese University of Hong Kong, New Territories, Hong Kong Short title: a powerful approach to detect cancer-driver genes * To whom correspondence should be addressed to Miaoxin Li. Tel: +86-2087335080; Email: [email protected] Medical Science and Technology Building, Zhongshan School of Medicine, Sun Yat-sen University, China. Yonghong Zhu. Tel: +86-20 87331451; Email: [email protected] Medical Science and Technology Building, Zhongshan School of Medicine, Sun Yat-sen University, China. Pak-Chung Sham. Tel: +852-28315425; Fax: +852-28185653; Email: [email protected]; The University of Hong Kong, 5 Sassoon Road, Pokfulam Hong Kong SAR”.
    [Show full text]
  • Rho-Associated Kinase 2 Polymorphism of Vasospastic
    Editorial http://dx.doi.org/10.4070/kcj.2012.42.6.379 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Korean Circulation Journal Rho-Associated Kinase 2 Polymorphism of Vasospastic Angina in Korean Population Chul Soo Park, MD Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Yeouido St. Mary’s Hospital, Seoul, Korea Refer to the page 406-413 periments, we can speculate that an increased activity of ROCKs can be one of the important pathophysiologic mechanisms of vaso- spastic angina, and fasudil, a ROCK inhibitor has exerted beneficial Rho-associated kinases (ROCKs), the immediate downstream effect on VA.4) targets of RhoA, are ubiquitously expressed serine-threonine pro- Rho-associated kinases could regulate other cellular functions tein kinases, which are involved in diverse cellular functions, includ- that are independent of their effects on the actin cytoskeleton. For ing smooth muscle contraction, actin cytoskeleton organization, cell examples, Rock inhibits insulin signaling, reduces cardiac hypertro- adhesion and motility, and gene expression. Recent studies have phy and involves an in tissue differentiation from adipocyte to myo- shown that ROCKs may play a pivotal role in cardiovascular diseases, cyte. such as vasospastic angina, ischemic stroke, and heart failure. In addition to ROCK’s effect on actin cytoskeleton system, inhibi- Rho-associated kinases are important regulators of cellular apop- tory effect on endothelial nitric oxide synthase (eNOS) activity can tosis, growth, metabolism, and migration via control of the actin cy- be another mechanism involved in the pathogenesis of vasospasm. toskeletal assembly and cell contraction.1) ROCKs phosphorylate var- Enothelium derived NO plays an important role in the regulation ious targets and mediate broad range of cellular responses that in- of vascular tone, inhibition of platelet aggregation, and the suppres- volve in actin cytoskeleton in response to GTPase-RhoA.
    [Show full text]
  • Impacts of Ciliary Neurotrophic Factor on the Retinal Transcriptome in a Mouse Model of Photoreceptor Degeneration
    www.nature.com/scientificreports OPEN Impacts of ciliary neurotrophic factor on the retinal transcriptome in a mouse model of photoreceptor degeneration Yanjie Wang1, Kun-Do Rhee1, Matteo Pellegrini2 & Xian-Jie Yang1* Ciliary neurotrophic factor (CNTF) has been tested in clinical trials for human retinal degeneration due to its potent neuroprotective efects in various animal models. To decipher CNTF-triggered molecular events in the degenerating retina, we performed high-throughput RNA sequencing analyses using the Rds/Prph2 (P216L) transgenic mouse as a preclinical model for retinitis pigmentosa. In the absence of CNTF treatment, transcriptome alterations were detected at the onset of rod degeneration compared with wild type mice, including reduction of key photoreceptor transcription factors Crx, Nrl, and rod phototransduction genes. Short-term CNTF treatments caused further declines of photoreceptor transcription factors accompanied by marked decreases of both rod- and cone-specifc gene expression. In addition, CNTF triggered acute elevation of transcripts in the innate immune system and growth factor signaling. These immune responses were sustained after long-term CNTF exposures that also afected neuronal transmission and metabolism. Comparisons of transcriptomes also uncovered common pathways shared with other retinal degeneration models. Cross referencing bulk RNA-seq with single-cell RNA-seq data revealed the CNTF responsive cell types, including Müller glia, rod and cone photoreceptors, and bipolar cells. Together, these results demonstrate the infuence of exogenous CNTF on the retinal transcriptome landscape and illuminate likely CNTF impacts in degenerating human retinas. Retinal degeneration (RD) is known as an irreversible, progressive neurologic disorder caused by genetic muta- tions and/or environmental or pathological damage to the retina.
    [Show full text]
  • Analysis of Microarray Data for Identification of Key Microrna Signatures in Glioblastoma Multiforme
    1938 ONCOLOGY LETTERS 18: 1938-1948, 2019 Analysis of microarray data for identification of key microRNA signatures in glioblastoma multiforme SANU K. SHAJI, DAMU SUNILKUMAR, N.V. MAHALAKSHMI, GEETHA B. KUMAR and BIPIN G. NAIR School of Biotechnology, Amrita Vishwa Vidyapeetham, Kollam, Kerala 690525, India Received December 15, 2018; Accepted June 6, 2019 DOI: 10.3892/ol.2019.10521 Abstract. Glioblastoma multiforme (GBM) is one of the most Introduction malignant types of glioma known for its reduced survival rate and rapid relapse. Previous studies have shown that the expres- Glioblastoma multiforme (GBM) is the most common and sion patterns of different microRNAs (miRNA/miR) play malignant types of glioma, accounting for the major cause of a crucial role in the development and progression of GBM. brain cancer death, with a median patient survival of about In order to identify potential miRNA signatures of GBM for 15 months from diagnosis (1). It is considered to be the 12th prognostic and therapeutic purposes, we downloaded and leading cause of cancer-associated death in the USA (2). analyzed two expression data sets from Gene Expression Treatment of GBM includes surgery, chemotherapy and Omnibus profiling miRNA patterns of GBM compared with radiation therapy, but resistance to chemotherapeutic agents normal brain tissues. Validated targets of the deregulated and a high frequency of relapse after surgery, pose difficul- miRNAs were identified using MirTarBase, and were mapped ties in the therapeutic intervention of this disease (3-5). The to Search Tool for the Retrieval of Interacting Genes/Proteins, molecular determinants of GBM are not well understood even Database for Annotation, Visualization and Integrated though there have been advances in GBM research in last few Discovery and Kyoto Encyclopedia of Genes and Genomes decades.
    [Show full text]
  • Supplemental Tables
    Supplemental Tables 1 (Up in 1 (Up in Log2 AD80) / 2 Log2 1 (Up in Log2 AD80) / 2 Fold (Low in Fold AD80) / 2 Fold Gene (Low in AD30) change Gene AD30) change Gene (Low in AD30) change G6PC 1 8.262795 SYT8 1 3.826244 SPATA9 1 3.10268 ADH1B 1 7.508264 ADH4 1 3.800391 SPTSSB 1 3.093815 RNU1-70P 1 6.596403 WNT8B 1 3.799741 CYP26A1 1 3.093672 CYP7A1 1 6.56167 TNFSF10 1 3.795007 ACR 1 3.092358 ADH1A 1 6.358759 HMGCS2 1 3.791218 DUOX2 1 3.090622 SLC2A2 1 6.05681 GNAT1 1 3.737262 SPTLC3 1 3.086353 TNFRSF14- AS1 1 6.055208 CFHR4 1 3.732386 FER1L5 1 3.081569 IGFALS 1 5.825777 BSND 1 3.718276 RASA4CP 1 3.080765 LINC00957 1 5.727226 TSPOAP1 1 3.709555 DOC2GP 1 3.057021 TTBK1 1 5.724558 SLC22A7 1 3.698323 VAT1L 1 3.051293 CYP3A43 1 5.674953 AOC4P 1 3.68655 FMO3 1 3.031314 HNF4A- UGT1A9 1 5.643359 AS1 1 3.679788 SFRP5 1 3.016623 APOL3 1 5.448612 FHAD1 1 3.665007 RFX6 1 3.015833 - VCAM1 1 5.442271 ADAMTS10 1 3.61034 SLC5A8 2 3.015901 BFSP2 1 5.396028 NUDT13 1 3.562774 LFNG 2 -3.01667 C22orf31 1 5.349548 FYTTD1P1 1 3.544783 CXCR4 2 -3.0544 FOXN1 1 5.19046 CHAD 1 3.534052 GPR3 2 -3.099 - A2MP1 1 5.186347 IRF5 1 3.517716 PA2G4P6 2 3.103813 - UROC1 1 5.056845 GSTA7P 1 3.504839 PRDM8 2 3.140796 - XAF1 1 5.053767 CXCL10 1 3.486513 DGKG 2 3.261431 - ADAMTS14 1 5.049252 SERPINA2 1 3.481204 BCAN 2 3.389266 - UGT1A8 1 5.048674 WDR93 1 3.475799 MMP10 2 3.411248 - TTLL11-IT1 1 4.965854 MAP6 1 3.465613 MYBPC3 2 3.492397 HRC 1 4.853162 MOV10L1 1 3.457172 MUC12 2 -3.55192 - MOGAT2 1 4.797347 HP 1 3.456436 FGF18 2 3.551928 - SEPT7P9 1 4.735573 MT1B 1 3.43852 MYO1G
    [Show full text]
  • Cyclin-Dependent Kinase 2 (Cdk2) Controls Phosphatase-Regulated Signaling and Function in Platelets
    bioRxiv preprint doi: https://doi.org/10.1101/2020.05.31.126953; this version posted June 28, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Cyclin-dependent kinase 2 (Cdk2) controls phosphatase-regulated signaling and function in platelets Paul R. Woods, Jr.,1,2 Brian L. Hood5, Sruti Shiva,$4 Thomas P. Conrads5, Sarah Suchko,2 Richard Steinman, 1,2,4# Departments oF Medicine1, Hillman Cancer Center2, Vascular Medicine Institute3, Department oF Molecular Pharmacology and Chemical Biology4, University of Pittsburgh School of Medicine; The Henry M. Jackson Foundation For the Advancement of Military Medicine, Inc., Inova Women’s Service Line, Inova Health System5 #Corresponding author: Richard Steinman, MD, PhD Associate Professor of Medicine and Pharmacology Associate Dean, Director Medical Scientist Training Program Director, Physician Scientist Training Program University of Pittsburgh School of Medicine 2.26f Hillman Cancer Center 5117 Centre Avenue Pittsburgh, PA 15213 USA phone: 412 6233237 fax: 412 6234840 [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2020.05.31.126953; this version posted June 28, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract Cell cycle regulatory molecules including cyclin-dependent kinases can be recruited into non-nuclear pathways to coordinate cell cycling with the energetic state oF the cell or with Functions such as motility.
    [Show full text]
  • (Slx-2119), a ROCK2-Specific Inhibitor, in 3T3-L1 Cells
    www.nature.com/scientificreports OPEN Anti-adipogenic efects of KD025 (SLx-2119), a ROCK2-specifc inhibitor, in 3T3-L1 cells Received: 6 January 2017 Duy Trong Vien Diep1, Kyungki Hong1, Triyeng Khun1, Mei Zheng 1, Asad ul-Haq1, Accepted: 24 January 2018 Hee-Sook Jun1,3,4, Young-Bum Kim2,3 & Kwang-Hoon Chun1 Published: xx xx xxxx Adipose tissue is a specialized organ that synthesizes and stores fat. During adipogenesis, Rho and Rho- associated kinase (ROCK) 2 are inactivated, which enhances the expression of pro-adipogenic genes and induces the loss of actin stress fbers. Furthermore, pan ROCK inhibitors enhance adipogenesis in 3T3-L1 cells. Here, we show that KD025 (formerly known as SLx-2119), a ROCK2-specifc inhibitor, suppresses adipogenesis in 3T3-L1 cells partially through a ROCK2-independent mechanism. KD025 downregulated the expression of key adipogenic transcription factors PPARγ and C/EBPα during adipogenesis in addition to lipogenic factors FABP4 and Glut4. Interestingly, adipogenesis was blocked by KD025 during days 1~3 of diferentiation; after diferentiation terminated, lipid accumulation was unafected. Clonal expansion occurred normally in KD025-treated cells. These results suggest that KD025 could function during the intermediate stage after clonal expansion. Data from depletion of ROCKs showed that KD025 suppressed cell diferentiation partially independent of ROCK’s activity. Furthermore, no further loss of actin stress fbers emerged in KD025-treated cells during and after diferentiation compared to control cells. These results indicate that in contrast to the pro-adipogenic efect of pan-inhibitors, KD025 suppresses adipogenesis in 3T3-L1 cells by regulating key pro- adipogenic factors.
    [Show full text]
  • Androgen-Regulated Microrna-135A Decreases Prostate Cancer Cell Migration and Invasion Through Downregulating ROCK1 and ROCK2
    Oncogene (2015) 34, 2846–2855 © 2015 Macmillan Publishers Limited All rights reserved 0950-9232/15 www.nature.com/onc ORIGINAL ARTICLE Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2 A Kroiss1, S Vincent1, M Decaussin-Petrucci1,2,3, E Meugnier4, J Viallet5, A Ruffion1,2,6, F Chalmel7, J Samarut1,2,8 and N Allioli1,9 Androgen signaling, via the androgen receptor (AR), is crucial in mediating prostate cancer (PCa) initiation and progression. Identifying new downstream effectors of the androgens/AR pathway will allow a better understanding of these mechanisms and could reveal novel biomarkers and/or therapeutic agents to improve the rate of patient survival. We compared the microRNA expression profiles in androgen-sensitive LNCaP cells stimulated or not with 1 nM R1881 by performing a high-throughput reverse transcriptase–quantitative PCR and found that miR-135a was upregulated. After androgen stimulation, we showed that AR directly activates the transcription of miR-135a2 gene by binding to an androgen response element in the promoter region. Our findings identify miR-135a as a novel effector in androgens/AR signaling. Using xenograft experiments in chick embryos and adult male mice, we showed that miR-135a overexpression decreases in vivo invasion abilities of prostate PC-3 cells. Through in vitro wound- healing migration and invasion assays, we demonstrated that this effect is mediated through downregulating ROCK1 and ROCK2 expression, two genes that we characterized as miR-135a direct target genes. In human surgical samples from prostatectomy, we observed that miR-135a expression was lower in tumoral compared with paired adjacent normal tissues, mainly in tumors classified with a high Gleason score (⩾8).
    [Show full text]
  • Hypoxia Transcriptomic Modifications Induced by Proton Irradiation In
    Journal of Personalized Medicine Article Hypoxia Transcriptomic Modifications Induced by Proton Irradiation in U87 Glioblastoma Multiforme Cell Line Valentina Bravatà 1,2,† , Walter Tinganelli 3,†, Francesco P. Cammarata 1,2,* , Luigi Minafra 1,2,* , Marco Calvaruso 1,2 , Olga Sokol 3 , Giada Petringa 2, Giuseppe A.P. Cirrone 2, Emanuele Scifoni 4 , Giusi I. Forte 1,2,‡ and Giorgio Russo 1,2,‡ 1 Institute of Molecular Bioimaging and Physiology–National Research Council (IBFM-CNR), 90015 Cefalù, Italy; [email protected] (V.B.); [email protected] (M.C.); [email protected] (G.I.F.); [email protected] (G.R.) 2 Laboratori Nazionali del SUD, Istituto Nazionale di Fisica Nucleare (LNS-INFN), 95100 Catania, Italy; [email protected] (G.P.); [email protected] (G.A.P.C.) 3 Biophysics Department, GSI Helmholtzzentrum für Schwerionenforschung GmbH, 64291 Darmstadt, Germany; [email protected] (W.T.); [email protected] (O.S.) 4 Trento Institute for Fundamental Physics and Applications (TIFPA), Istituto Nazionale Fisica Nucleare (INFN), 38123 Trento, Italy; [email protected] * Correspondence: [email protected] (F.P.C.); [email protected] (L.M.) † These authors contributed equally to this work. ‡ These authors contributed equally to this work. Abstract: In Glioblastoma Multiforme (GBM), hypoxia is associated with radioresistance and poor prognosis. Since standard GBM treatments are not always effective, new strategies are needed Citation: Bravatà, V.; Tinganelli, W.; to overcome resistance to therapeutic treatments, including radiotherapy (RT). Our study aims Cammarata, F.P.; Minafra, L.; to shed light on the biomarker network involved in a hypoxic (0.2% oxygen) GBM cell line that Calvaruso, M.; Sokol, O.; Petringa, G.; is radioresistant after proton therapy (PT).
    [Show full text]